Markolf Hanefeld

Summary

Affiliation: Centre for Clinical Studies
Country: Germany

Publications

  1. ncbi request reprint Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis
    Elena Henkel
    Centre for Clinical Studies Metabolism and Endocrinology, GWT TU Dresden, Technical University Dresden, Fiedlerstrasse 34, D 01307 Dresden, Germany
    Blood Coagul Fibrinolysis 18:327-34. 2007
  2. ncbi request reprint Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes
    M Hanefeld
    Centre for Clinical Studies GWT TU Dresden, Technical University, Dresden, Germany
    Diabetes Res Clin Pract 55:221-7. 2002
  3. ncbi request reprint Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance
    Markolf Hanefeld
    Centre for Clinical Studies, Dresden Technical University, Dresden, Germany
    Stroke 35:1073-8. 2004
  4. ncbi request reprint [The metabolic syndrome and its epidemiologic dimensions in historical perspective]
    Markolf Hanefeld
    Zentrum für Klinische Studien, Forschungsbereich Endokrinologie und Stoffwechsel, GWT, TU Dresden
    Z Arztl Fortbild Qualitatssich 96:183-8. 2002
  5. ncbi request reprint Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies
    M Hanefeld
    Centre for Clinical Studies, GWT, Technical University of Dresden, Fiedlerstrasse 34, 01307 Dresden, Germany
    Eur Heart J 25:10-6. 2004
  6. ncbi request reprint Control of post-prandial hyperglycemia--an essential part of good diabetes treatment and prevention of cardiovascular complications
    M Hanefeld
    Center of Clinical Studies, Technical University Dresden, Fiedlerstrasse 34, 01307 Dresden, Germany
    Nutr Metab Cardiovasc Dis 12:98-107. 2002
  7. ncbi request reprint [Differential type 2 diabetes therapy based on pathophysiological aspects]
    M Hanefeld
    Zentrum für Klinische Studien, GWT TU Dresden
    Ther Umsch 59:393-401. 2002
  8. ncbi request reprint One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes
    Markolf Hanefeld
    Centre for Clinical Studies, GWT Technical University, Dresden, Germany
    Diabetes Care 27:141-7. 2004
  9. ncbi request reprint Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study
    Markolf Hanefeld
    Centre for Clinical Studies, Gesellschaft für Wissens und Technologietransfer, Technical University Dresden, Dresden, Germany
    Diabetes Care 26:868-74. 2003
  10. ncbi request reprint Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus
    Elena Henkel
    Centre for Clinical Studies Metabolism and Endocrinology, Science and Technology Transfer, Technical University, D 01307 Dresden, Germany
    Metabolism 54:1168-73. 2005

Detail Information

Publications52

  1. ncbi request reprint Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis
    Elena Henkel
    Centre for Clinical Studies Metabolism and Endocrinology, GWT TU Dresden, Technical University Dresden, Fiedlerstrasse 34, D 01307 Dresden, Germany
    Blood Coagul Fibrinolysis 18:327-34. 2007
    ..05). Besides the already established determinants, we found an independent association between glucagon and fibrinolysis in NGT. Further studies are needed to identify the link between glucagon, insulin resistance and hemostasis...
  2. ncbi request reprint Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes
    M Hanefeld
    Centre for Clinical Studies GWT TU Dresden, Technical University, Dresden, Germany
    Diabetes Res Clin Pract 55:221-7. 2002
    ..In a double-blind, placebo-controlled study, we compared the effect of acarbose (A) and glibenclamide (G) on post-prandial (pp) and 24-h profiles of proinsulin and insulin...
  3. ncbi request reprint Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance
    Markolf Hanefeld
    Centre for Clinical Studies, Dresden Technical University, Dresden, Germany
    Stroke 35:1073-8. 2004
    ..This article reports on a placebo-controlled subgroup analysis of the STOP-NIDDM study to examine the efficacy of acarbose to slow progression of intima-media thickness (IMT) in subjects with IGT...
  4. ncbi request reprint [The metabolic syndrome and its epidemiologic dimensions in historical perspective]
    Markolf Hanefeld
    Zentrum für Klinische Studien, Forschungsbereich Endokrinologie und Stoffwechsel, GWT, TU Dresden
    Z Arztl Fortbild Qualitatssich 96:183-8. 2002
    ..Today the metabolic syndrome is--and for the near future will continue to be--the most important source of new diabetics, as well as a major cause of coronary heart disease...
  5. ncbi request reprint Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies
    M Hanefeld
    Centre for Clinical Studies, GWT, Technical University of Dresden, Fiedlerstrasse 34, 01307 Dresden, Germany
    Eur Heart J 25:10-6. 2004
    ..To assess if treatment with the alpha-glucosidase inhibitor acarbose can reduce cardiovascular events in type 2 diabetic patients...
  6. ncbi request reprint Control of post-prandial hyperglycemia--an essential part of good diabetes treatment and prevention of cardiovascular complications
    M Hanefeld
    Center of Clinical Studies, Technical University Dresden, Fiedlerstrasse 34, 01307 Dresden, Germany
    Nutr Metab Cardiovasc Dis 12:98-107. 2002
    ..This article reviews the relationship between the control of post-prandial hyperglycemia and diabetes-related complications...
  7. ncbi request reprint [Differential type 2 diabetes therapy based on pathophysiological aspects]
    M Hanefeld
    Zentrum für Klinische Studien, GWT TU Dresden
    Ther Umsch 59:393-401. 2002
    ..Instead of a stepwise treatment algorithm an individualized therapy based on pathophysiology and comorbidities taking into account the global risk seems to be beneficial...
  8. ncbi request reprint One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes
    Markolf Hanefeld
    Centre for Clinical Studies, GWT Technical University, Dresden, Germany
    Diabetes Care 27:141-7. 2004
    ..The goal was to assess the 1-year efficacy and safety of the addition of pioglitazone or metformin to existing sulfonylurea (SU) therapy in patients with inadequately controlled type 2 diabetes...
  9. ncbi request reprint Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes study
    Markolf Hanefeld
    Centre for Clinical Studies, Gesellschaft für Wissens und Technologietransfer, Technical University Dresden, Dresden, Germany
    Diabetes Care 26:868-74. 2003
    ..This study compared both categories with respect to the degree of insulin secretion abnormalities and insulin resistance...
  10. ncbi request reprint Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus
    Elena Henkel
    Centre for Clinical Studies Metabolism and Endocrinology, Science and Technology Transfer, Technical University, D 01307 Dresden, Germany
    Metabolism 54:1168-73. 2005
    ..Prospective studies are needed to evaluate the impact of glucagon on the progression of glucose intolerance and the possible effects of medicinal suppression of glucagon increment to prevent the progression of glucose tolerance...
  11. doi request reprint Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial
    Markolf Hanefeld
    Centre for Clinical Studies, GWT TUD GmbH, Fiedlerstr 34, 01307 Dresden, Germany
    Diab Vasc Dis Res 6:32-7. 2009
    ..5 in those without MetS. In conclusion, most single traits and overall MetS label a very high-risk group in people with IGT. People with MetS reach a NNT to prevent development of new diabetes with acarbose of 5.8...
  12. doi request reprint Effect of acarbose on vascular disease in patients with abnormal glucose tolerance
    Markolf Hanefeld
    Center for Clinical Studies, GWT TUD GmbH, Dresden, Germany
    Cardiovasc Drugs Ther 22:225-31. 2008
    ..This is associated with pleiotropic effects on a broad spectrum of cardiovascular (CV) risk factors: reduction of overweight, lowering of blood pressure, triglycerides, hsCRP, fibrinogen and other biomarkers of low grade inflammation...
  13. ncbi request reprint Treatment of impaired glucose tolerance with acarbose and its effect on intima-media thickness: a substudy of the STOP-NIDDM trial (study to prevent non-insulin-dependent diabetes mellitus)
    Markolf Hanefeld
    Centre for Clinical Studies, GWT Technical University, Dresden, Germany
    Endocr Pract 12:56-9. 2006
    ..To discuss the influence of glucose excursions on intima-media thickness (IMT) and the potential benefits of treatment to reduce or reverse its effects on cardiovascular risk...
  14. doi request reprint Acarbose: oral anti-diabetes drug with additional cardiovascular benefits
    Markolf Hanefeld
    Centre for Clinical Studies, Dresden, Fiedlerstrasse 34, 01307 Dresden, Germany
    Expert Rev Cardiovasc Ther 6:153-63. 2008
    ..It can be given alone or in combination with other oral antidiabetics and insulin. Acarbose is particularly effective in those with IGT and early diabetes and patients with comorbidities of the metabolic syndrome...
  15. pmc Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes
    Markolf Hanefeld
    Zentrum für Klinische Studien, GWT, Technische Universitat Dresden, Dresden, Germany
    Cardiovasc Diabetol 6:20. 2007
    ....
  16. ncbi request reprint In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control
    Frank Pistrosch
    Nephrology, Department of Medicine, University Hospital Dresden, Dresden, Germany
    Diabetes Care 27:484-90. 2004
    ..Conceivably, endothelial dysfunction could be involved. Therefore, we asked whether therapy for insulin resistance ameliorates any endothelial dysfunction...
  17. ncbi request reprint Leukocyte count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetes
    Theodora Temelkova-Kurktschiev
    Centre for Clinical Studies Metabolism and Endocrinology, Science and Technology Transfer, Technical University Dresden, Fiedlerstr 34, 01307, Dresden, Germany
    Cardiovasc Res 56:277-83. 2002
    ....
  18. pmc Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the
    Markolf Hanefeld
    GWT TUD mbH, Fiedlerstr 34, 01307 Dresden, Germany
    Cardiovasc Diabetol 10:65. 2011
    ..We analyzed specific effects of an add-on therapy with pioglitazone compared to metformin and their combination in patients with basal insulin treatment on biomarkers of CV risk...
  19. ncbi request reprint Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes
    Markolf Hanefeld
    GWT Technical University, Dresden, Germany
    Curr Med Res Opin 23:1329-39. 2007
    ..Additionally, the glycemic response to sitagliptin 100 mg daily was evaluated as a once-daily (100 mg once-daily) or twice-daily (50 mg twice-daily) dosing regimen...
  20. ncbi request reprint A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes
    Markolf Hanefeld
    Centre for Clinical Studies, GWT Technical University, Dresden, Germany
    Nutr Metab Cardiovasc Dis 17:13-23. 2007
    ..This study was designed to compare the efficacy of rosiglitazone and glibenclamide in individuals with type 2 diabetes over a 12-month period...
  21. doi request reprint Conversion of IGT to type 2 diabetes mellitus is associated with incident cases of hypertension: a post-hoc analysis of the STOP-NIDDM trial
    Markolf Hanefeld
    Center for Clinical Studies, Technical University Dresden, Dresden, Germany
    J Hypertens 30:1440-3. 2012
    ..However, there is little information available about the relationship between incidence of hypertension and a deterioration of glucose tolerance from impaired glucose tolerance (IGT) to diabetes...
  22. ncbi request reprint Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis
    Theodora Temelkova-Kurktschiev
    Center for Clinical Studies, Technical University Dresden, Fiedlerstrasse 34, 01307 Dresden, Germany
    J Clin Endocrinol Metab 89:4238-42. 2004
    ..In conclusion, our data suggest that the Ala(12)Ala genotype of the PPARgamma2 gene may protect from early atherosclerosis in subjects at risk for diabetes...
  23. ncbi request reprint Relationship between diurnal blood pressure variation and diurnal blood glucose levels in type 2 diabetic patients
    Frank Pistrosch
    Department of Medicine, Nephrology, University Hospital, Dresden, Germany
    Am J Hypertens 20:541-5. 2007
    ..We therefore investigated the relationship between diurnal hyperglycemia and diurnal blood pressure (BP) variation in patients...
  24. ncbi request reprint Elevated fasting glucose levels predicts IGT and diabetes also in middle-age subjects
    Peter E H Schwarz
    Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl Gustav Carus of the Technical University Dresden, Fetscherstrasse 74, Dresden, Germany
    Diabetes Res Clin Pract 77:148-50. 2007
    ..We therefore conclude that elevated fasting glucose levels in the "IFG" category predict the development of IGT/diabetes in a middle-age population...
  25. pmc Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study
    Markolf Hanefeld
    Center for Clinical Studies Metabolism and Endocrinology, Science and Technology Transfer, TU Dresden, Dresden, Germany
    Cardiovasc Diabetol 6:13. 2007
    ..We aimed to answer this by evaluating the relationship, and its various combinations to AVD in comparison to single traits in a population-based study with type 2 diabetes in Germany...
  26. doi request reprint Evaluation of a diabetes management system based on practice guidelines, integrated care, and continuous quality management in a Federal State of Germany: a population-based approach to health care research
    Ulrike Rothe
    Institute for Medical Informatics and Biometrics, Medical Faculty Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
    Diabetes Care 31:863-8. 2008
    ..The SDMP was implemented into diabetes contracts between health insurance providers, general practitioners (GPs), and diabetes specialized practitioners (DSPs) unified in the Saxon association of Statutory Health Insurance Physicians...
  27. ncbi request reprint [Metabolic syndrome: "common soil" for diabetes and atherosclerosis. Novel approaches to an integrated therapy]
    Markolf Hanefeld
    Zentrum für Klinische Studien der GWT TUD GmbH, Fiedlerstrasse 74, 01307, Dresden, Germany
    Herz 31:246-54; quiz 255. 2006
    ..The strategy using synergies in drug treatment can reduce polypharmacy and costs and improve the patients' compliance...
  28. ncbi request reprint Hypoadiponectinemia is associated with progression toward type 2 diabetes and genetic variation in the ADIPOQ gene promoter
    Peter E H Schwarz
    Department of Endocrinopathies and Metabolic Diseases, Medical Faculty Carl Gustav Carus of the Technical University Dresden, Medical Clinic III, Building 46, Room 10, Fetscherstrasse 74, 01309, Dresden, Germany
    Diabetes Care 29:1645-50. 2006
    ..The aim of the current study was to investigate whether ADIPOQ gene variants in the promoter region predict adiponectin levels and type 2 diabetes progression...
  29. ncbi request reprint [Postprandial hyperglycemia as a risk factor for cardiovascular disease. Therapy improves prognosis]
    Markolf Hanefeld
    Zentrum für Klinische Studien, Gesellschaft für Wissens und Technologietransfer der TU Dresden mbH, Dresden, Deutschland
    Herz 29:480-7. 2004
    ..Thus control of the glucose trias-HbA(1c), postprandial and fasting plasma glucoses is essentially practice in patients with cardiovascular disease...
  30. ncbi request reprint Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study
    Markolf Hanefeld
    GWT, Center for Clinical Studies, Dresden, Germany
    J Am Coll Cardiol 49:290-7. 2007
    ....
  31. ncbi request reprint Oral glucose tolerance test: to be or not to be performed?
    Theodora S Temelkova-Kurktschiev
    Science and Technology Transfer, Centre for Clinical Studies, Metabolism and Endocrinology, Technical University Dresden, Germany
    Clin Lab 48:143-52. 2002
    ..Since an OGTT cannot be generally conducted, we recommend its performance in risk subjects and especially in elderly women. This would make it possible to institute preventive measures...
  32. ncbi request reprint [Multimodal therapy of dyslipidemia]
    Annett Stahn
    Zentrum für Klinische Studien, Fiedlerstraße 34, Dresden, Germany
    Clin Res Cardiol Suppl 6:10-6. 2011
    ..In the future a recommendation for the treatment of mixed hyperlipoproteinemia with decreased HDL, raised triglycerides and LDL-cholesterol shall have to be added to our guidelines...
  33. ncbi request reprint In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance
    Steffi Kopprasch
    Department of Internal Medicine 3, Carl Gustav Carus Medical School, University of Technology Dresden, Germany
    Diabetes 51:3102-6. 2002
    ..OxLDL increase may explain the high atherogenic potency of dyslipidemia in the prediabetic state...
  34. doi request reprint Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia
    Zvonko Milicevic
    Eli Lilly Regional Operations, Vienna, Austria
    Diabetes Care 31:S155-60. 2008
    ..Based on the results of epidemiological reports, the most appropriate targets in interventional trials are postprandial hyperglycemia or A1C...
  35. ncbi request reprint Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
    Jean Louis Chiasson
    Research Centre, Centre Hospitalier de l Universite de Montreal, Hotel Dieu, Department of Medicine, University of Montreal, Quebec, Canada
    Lancet 359:2072-7. 2002
    ..The worldwide increase in type 2 diabetes mellitus is becoming a major health concern. We aimed to assess the effect of acarbose in preventing or delaying conversion of impaired glucose tolerance to type 2 diabetes...
  36. ncbi request reprint [In high risk for diabetes should drugs be used for prevention? (interview by Dr. Judith Neumaier)]
    Markolf Hanefeld
    MMW Fortschr Med 144:12. 2002
  37. doi request reprint Guideline for management of postmeal glucose
    Antonio Ceriello
    Warwick Medical School, Clinical Science Research Institute, Clinical Science Building, University Hospital Walsgrave Campus, Clifford Bridge Road, Coventry CV2 2DX, UK
    Nutr Metab Cardiovasc Dis 18:S17-33. 2008
    ..This guideline reviews the evidence on the harmful effects of elevated postmeal glucose and makes recommendations on its treatment, assessment and targets...
  38. ncbi request reprint Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial
    Jean Louis Chiasson
    Research Centre, Centre Hospitalier de l Université de Montréal Hôtel Dieu and Department of Medicine, Universite de Montreal, Montreal, Quebec, Canada
    JAMA 290:486-94. 2003
    ..The worldwide explosive increase in type 2 diabetes mellitus and its cardiovascular morbidity are becoming major health concerns...
  39. ncbi request reprint Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis
    Philip D Home
    Newcastle Diabetes Centre and Newcastle University, Newcastle upon Tyne, United Kingdom
    N Engl J Med 357:28-38. 2007
    ..A recent meta-analysis raised concern regarding an increased risk of myocardial infarction and death from cardiovascular causes associated with rosiglitazone treatment of type 2 diabetes...
  40. pmc Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study)
    Michel Komajda
    Université Pierre et Marie Curie Paris 6 Assistance Publique Hôpitaux de Paris, Hopital Pitie Salpetriere, Paris, France
    Cardiovasc Diabetol 7:10. 2008
    ..We therefore used ambulatory BP to quantify BP lowering at 6-12 months with rosiglitazone used in combination with metformin or sulfonylureas compared to metformin and sulfonylureas in people with type 2 diabetes...
  41. ncbi request reprint Prandial hyperglycemia: is it important to track and treat?
    Markolf Hanefeld
    Centre of Clinical Studies, GWT Technical University Dresden, Fiedlerstrasse, Dresden 34 01307, Germany
    Curr Diab Rep 5:333-9. 2005
    ..Prospective trials have demonstrated that strict control of postprandial hyperglycemia reduces the incidence of cardiovascular events...
  42. ncbi request reprint Fluctuations in glycaemia in clinical diabetes mellitus type 2 are not associated with carotid intima-media thickening
    Katharina Karrei
    Diab Vasc Dis Res 1:51-2. 2004
  43. ncbi request reprint Postprandial glucose regulation: new data and new implications
    Lawrence A Leiter
    St Michael s Hospital, University of Toronto, Toronto, Canada
    Clin Ther 27:S42-56. 2005
    ..However, physicians continue to rely on fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1c) to guide management...
  44. ncbi request reprint Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy
    Christof Kazda
    Lilly Deutschland GmbH, Bad Homburg, Germany
    J Diabetes Complications 20:145-52. 2006
    ..To compare the effects of prandial insulin therapy focusing on postprandial glucose control vs. basal insulin therapy focusing on fasting glucose control in patients with type 2 diabetes...
  45. ncbi request reprint Postprandial glucose regulation and diabetic complications
    Antonio Ceriello
    Department of Pathology and Medicine Experimental and Clinical, University of Udine, Udine, Italy
    Arch Intern Med 164:2090-5. 2004
    ..The present review examines the hypothesis that controlling postprandial glucose level is an important strategy in the prevention of cardiovascular complications associated with diabetes...
  46. ncbi request reprint Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update
    Antonio Ceriello
    Clinical Science Research Institute, Clinical Science Building, Warwick Medical School, University of Warwick, Coventry, UK
    Nutr Metab Cardiovasc Dis 16:453-6. 2006
    ..Therefore, in addition to HbA1c and FPG, physicians should consider monitoring and targeting PPG in patients with type 2 diabetes...
  47. ncbi request reprint Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study
    Thomas Forst
    Institute for Clinical Research and Development, Medical Department, D 55116 Mainz, Germany
    Metabolism 56:491-6. 2007
    ..05) during PIO/SIM treatment. Lipid parameters improved during SIM treatment but not during PIO treatment. Combined treatment with PIO/SIM was superior in improving overall cardiovascular risk profile than every single drug...
  48. ncbi request reprint Association of the calpain-10 gene with type 2 diabetes in Europeans: results of pooled and meta-analyses
    Takafumi Tsuchiya
    Departments of Medicine and Human Genetics, The University of Chicago, 5841 S Maryland Ave, MC1027, Chicago, IL 60637, USA
    Mol Genet Metab 89:174-84. 2006
    ..68 (1.33-2.11), P=0.00001). The pooled and meta-analyses as well as the linkage disequilibrium and haplotype diversity studies suggest a role for genetic variation in CAPN10 affecting risk of T2D in Europeans...
  49. doi request reprint The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-bl
    Emile R Mohler
    University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    J Am Coll Cardiol 51:1632-41. 2008
    ..This study examined the effects of darapladib, a selective lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) inhibitor, on biomarkers of cardiovascular (CV) risk...
  50. ncbi request reprint Alpha-glucosidase inhibitors for patients with type 2 diabetes: response to van de Laar et al
    Markolf Hanefeld
    Diabetes Care 28:1840; author reply 1841. 2005
  51. ncbi request reprint The effect of glucose variability on the risk of microvascular complications in type 1 diabetes
    Louis Monnier
    Diabetes Care 30:185-6; author reply 187-8. 2007
  52. ncbi request reprint Introduction: new approaches to managing diabetic dyslipidaemia
    Markolf Hanefeld
    Atheroscler Suppl 6:1-2. 2005